Publication | Open Access

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Biosimilar Ct-p13Originator InfliximabGastroenterologyClinical GastroenterologyUlcerative ColitisMedicineRadiologyActive Crohn